Cell Viability Assays Market Research Report – Forecast to 2023

Global Cell Viability Assays Research Report: By Product (Consumables, Instruments), by Cell Type (Human Cells, Microbial Cells, Animal cells), by Application (Stem Cell Research & Others), End-User (Pharma Biotech Companies & Others)– Forecast Till 2023

ID: MRFR/LS/4930-HCR | February 2021 | Region: Global | 90 pages

Market Scenario


Global cell Viability Assays market is expected to grow significantly over the forecast period. It is estimated that the global cell Viability Assays market is expected to register a CAGR ~ 9.2% during the forecast period of 2018–2023.


Cell Viability Assays is a type of technique used for determining viable cells in the culture. Cell Viability Assays asses the efficiency of the cells by measuring markers of cellular activity. The cell viability is used to monitor the response and health of the cells in the culture after treatment with various stimuli. Moreover, cell Viability Assays and cytotoxicity assays are used for drug screening and cytotoxicity tests of chemicals.


Numerous factors such as growing prevalence of chronic and infectious diseases, growing availability of funds for cell-based research, rising need of cell-based assays in research and development activities are expected to drive the growth of the market. For instance, in 2015, the National Institutes of Health invested around 1,429 million USD for stem cells research. Moreover, increasing focus on developing cell-based therapeutics boosts the growth of the market. However, the rising cost of the instruments may hamper the market growth during the assessment period.


Segmentation


The market has been segmented into products, cell type, applications, and end-user.


The market, on the basis of products, has been segmented into consumables and instruments.


The consumables segment has been further divided into reagents, assay kits, and microplates. The Assay kits segment has been further segmented into tetrazolium reduction assay kits, resazurin cell Viability Assays kits, calcein-Am cell Viability Assays kits and other assay kits. Furthermore, tetrazolium assay kits have been classified into MIT assay kits and other tetrazolium assay kits.


The instruments have been segmented into automated cell counters, flow cytometers, spectrophotometers, and cell imaging & analysis systems.


The market, by cell type, has been segmented into human cells, microbial cells, and animal cells.


The market, by applications, has been segmented into stem cell research, clinical & diagnostic applications, drug discovery & development, and others.


The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & diagnostic laboratories and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cell Viability Assays market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European cell Viability Assays market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The cell Viability Assays market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cell Viability Assays market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton Dickinson & Company, Promega Corporation, Biotium, Abcam plc, Creative Bioarray, Biotek Instruments, and PerkinElmer are some of the key players in the global cell Viability Assays market.


Regional Market Summary


Global Cell Viability Assays Market Share (%), by Region, 2017


Cell Viability Assays Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global cell Viability Assays market owing to a well-developed healthcare sector, rising prevalence of infectious and chronic diseases and growing healthcare expenditure. According to an article published by the Centers for Medicare and Medicaid Services in August 2018, the US healthcare spending had reached USD 3.3 trillion in 2016. Europe is expected to hold the second largest position in the global cell Viability Assays market. The market growth in this region is attributed to the growing prevalence of chronic diseases and increasing healthcare expenditure. According to a report published by EU observer in September 2014, more than the one-third population of Europe above the age of 15 years in suffering from a chronic disease and 2 in every 3 people reaching the age of retirement have at least 2 chronic diseases.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising number of stem cell, proteomics, and genomics research activities. Also, increased expenditure in the healthcare sector is expected to boost the growth in this market.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Cell Viability Assays Market, by Products



  • Consumables



  • Reagents

  • Assay Kits

  • Tetrazolium reduction assay kits

  • MIT assay kits

  • Other Tetrazolium reduction assay kits

  • Resazurin cell Viability Assays kits

  • Calcein-Am cell Viability Assays kits

  • Other assay kits

  • Microplates



  • Instruments



  • Automated cell counters

  • Flow Cytometers

  • Spectrophotometers

  • Cell imaging and analysis systems


Global Cell Viability Assays Market, by Cell Type



  • Human Cells

  • Microbial Cells

  • Animal Cells


Global Cell Viability Assays Market, by Applications



  • Stem Cell research

  • Clinical and diagnostic applications

  • Drug discovery and development

  • Others


Global Cell Viability Assays Market, by End-user



  • Pharmaceutical and Biotechnology companies

  • Academic and research institutes

  • Hospital and diagnostic laboratories

  • Others


Global Cell Viability Assays Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa


Global Cell Viability Assays Market, by Key Players



  • Thermo Fisher Scientific

  • Merck KGaA

  • Bio-Rad Laboratories

  • G E Healthcare

  • Danaher Corporation

  • Becton, Dickinson and Company

  • Promega Corporation

  • Biotium

  • Abcam plc

  • Creative Bioarray

  • Biotek Instruments

  • PerkinElmer


Intended Audience



  • Pharmaceutical and Biopharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Table of Contents:


Chapter 1. Report Prologue


Chapter 2. Market Introduction


2.1 Definition


2.2 Scope of the Study


2.2.1 Research Objective


2.2.2 Assumptions


2.2.3 Limitations


Chapter 3. Research Methodology


3.1 Introduction


3.2 Primary Research


3.3 Secondary Research


3.4 Market Size Estimation


Chapter 4. Market Dynamics


4.1 Drivers


4.2 Restraints


4.3 Opportunities


4.4 Challenges


4.5 Macroeconomic Indicators


4.6 Technology Trends & Assessment


Chapter 5. Market Factor Analysis


5.1 Porter’s Five Forces Analysis


5.1.1 Bargaining Power of Suppliers


5.1.2 Bargaining Power of Buyers


5.1.3 Threat of New Entrants


5.1.4 Threat of Substitutes


5.1.5 Intensity of Rivalry


5.2 Value Chain Analysis


5.3 Investment Feasibility Analysis


5.4 Pricing Analysis


Chapter 6. Global Cell Viability Assays Market, by Product


6.1 Introduction


6.2 Consumables


6.2.1 Reagents


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.2.2 Assay Kits


6.2.2.1 Tetrazolium Reduction Assay Kits


6.2.2.1.1 MIT Assay Kits


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.2.2.1.2 Other Tetrazolium Assay Kits


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.2.2.2 Resazurin Cell Viability Assay Kits


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.2.2.3 Calcein-Am Cell Viability Assay Kits


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.2.2.4 Other Assay Kits


6.2.3 Microplates


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.3 Instruments


6.3.1 Automated Cell Counters


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.3.2 Flow Cytometers


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.3.3 Spectrophotometers


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


6.3.4 Cell Imaging and Analysis Systems


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


Chapter 7. Global Cell Viability Assays Market, by Cell Type


7.1 Introduction


7.2 Human Cells


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


7.3 Microbial Cells


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


7.4 Animal Cells


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


Chapter 8. Global Cell Viability Assays Market, by Application


8.1 Introduction


8.2 Stem Cell Research


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


8.3 Clinical and Diagnostic Applications


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


8.4 Drug Discovery and Development


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


8.5 Others


Chapter 9. Global Cell Viability Assays Market, by End-User


9.1 Pharmaceutical and Biotechnology Companies


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


9.2 Academic and Research Institutes


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


9.3 Hospital and Diagnostic Centers


Market Estimates & Forecast, by Region, 2018–2023


Market Estimates & Forecast, by Country, 2018–2023


9.4 Others


Chapter 10. Global Cell Viability Assays Market, by Region


10.1 Introduction


10.2 Americas


10.2.1 North America


9.2.1.1 US


9.2.1.2 Canada


10.2.2 South America


10.3 Europe


10.3.1 Western Europe


10.3.1.1 Germany


10.3.1.2 France


10.3.1.3 Italy


10.3.1.4 Spain


10.3.1.5 UK


10.3.1.6 Rest of Western Europe


10.3.2 Eastern Europe


10.4 Asia-Pacific


10.4.1 Japan


10.4.2 China


10.4.3 India


10.4.4 Australia


10.4.5 South Korea


10.4.6 Rest of Asia-Pacific


10.5 Middle East & Africa


10.5.1 Middle East


10.5.2 Africa


Chapter 11. Company Landscape


11.1 Introduction


11.2 Market Share Analysis


11.3 Key Development & Strategies


Chapter 12. Company Profiles


12.1 Thermo Fisher Scientific


12.1.1 Company Overview


12.1.2 Product Overview


12.1.3 Financials Overview


12.1.4 Key Developments


12.1.5 SWOT Analysis


12.2 Merck KGaA


12.2.1 Company Overview


12.2.2 Product Overview


12.2.3 Financial Overview


12.2.4 Key Developments


12.2.5 SWOT Analysis


12.3 Bio-Rad Laboratories


12.3.1 Company Overview


12.3.2 Product Overview


12.3.3 Financial Overview


12.3.4 Key Development


12.3.5 SWOT Analysis


12.4 GE Healthcare


12.4.1 Company Overview


12.4.2 Product Overview


12.4.3 Financial Overview


12.4.4 Key Development


12.4.5 SWOT Analysis


12.5 Danaher Corporation


12.5.1 Company Overview


12.5.2 Product Overview


12.5.3 Financial overview


12.5.4 Key Developments


12.5.5 SWOT Analysis


12.6 Becton, Dickinson and Company


12.6.1 Company Overview


12.6.2 Product Overview


12.6.3 Financial Overview


12.6.4 Key Developments


12.6.5 SWOT Analysis


12.7 Promega Corporation


12.7.1 Overview


12.7.2 Product Overview


12.7.3 Financial Overview


12.7.4 Key Developments


12.7.5 SWOT Analysis


12.8 Biotium


12.8.1 Overview


12.8.2 Product Overview


12.8.3 Financials


12.8.4 Key Developments


12.8.5 SWOT Analysis


12.9 Abcam plc


12.9.1 Overview


12.9.2 Product Overview


12.9.3 Financials


12.9.4 Key Developments


12.9.5 SWOT Analysis


12.10 Creative Bioarray


12.10.1 Overview


12.10.2 Product Overview


12.10.3 Financials


12.10.4 Key Developments


12.10.5 SWOT Analysis


12.11 Biotek Instruments


12.11.1 Overview


12.11.2 Product Overview


12.11.3 Financials


12.11.4 Key Developments


12.11.5 SWOT Analysis


12.12 PerkinElmer


12.12.1 Overview


12.12.2 Product Overview


12.12.3 Financials


12.12.4 Key Developments


12.12.5 SWOT Analysis


Chapter 13 MRFR Conclusion


13.1 Key Findings


13.1.1 From CEO’s Viewpoint


13.1.2 Unmet Needs of the Market


13.2 Key Companies to Watch


13.3 Predictions for the Cell Viability Assays Industry


Chapter 14. Appendix




LIST OF TABLES


Table 1 Global Cell Viability Assays Market Synopsis, 2018–2023


Table 2 Global Cell Viability Assays Market Estimates and Forecast, 2018–2023 (USD Million)


Table 3 Global Cell Viability Assays Market, by Region, 2018–2023 (USD Million)


Table 4 Global Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 5 Global Cell Viability Assays Market, by Cell Type, 2018–2023(USD Million)


Table 6 Global Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 7 Global Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 8 North America: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 9 North America: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 10 North America: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 11 North America: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 12 US: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 13 US: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 14 US: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 15 US: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 16 Canada: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 17 Canada: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 18 Canada: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 19 Canada: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 20 South America: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 21 South America: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 22 South America: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 23 South America: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 24 Europe: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 25 Europe: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 26 Europe: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 27 Europe: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 28 Western Europe: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 29 Western Europe: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 30 Western Europe: Cell Viability Assays Market, by Application, 2018–2023 (USD


Million)


Table 31 Western Europe: Cell Viability Assays Market, by End-User, 2018–2023 (USD


Million)


Table 32 Eastern Europe: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 33 Eastern Europe: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 34 Eastern Europe: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 35 Eastern Europe: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 36 Asia-Pacific: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 37 Asia-Pacific: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 38 Asia-Pacific: Cell Viability Assays Market, by Application, 2018–2023 (USD Million)


Table 39 Asia-Pacific: Cell Viability Assays Market, by End-User, 2018–2023 (USD Million)


Table 40 Middle East & Africa: Cell Viability Assays Market, by Product, 2018–2023 (USD Million)


Table 41 Middle East & Africa: Cell Viability Assays Market, by Cell Type, 2018–2023 (USD Million)


Table 42 Middle East & Africa: Cell Viability Assays Market, by Application, 2018–2023 (USD


Million)


Table 43 Middle East & Africa: Cell Viability Assays Market, by End-User, 2018–2023 (USD


Million)


LIST OF FIGURES


Figure 1 Research Process


Figure 2 Segmentation for Global Cell Viability Assays Market


Figure 3 Segmentation Market Dynamics for Global Cell Viability Assays Market


Figure 4 Global Cell Viability Assays Market Share, by Product, 2017


Figure 5 Global Cell Viability Assays Market Share, by Cell Type, 2017


Figure 6 Global Cell Viability Assays Market Share, by Application, 2017


Figure 7 Global Cell Viability Assays Market Share, by End-User, 2017


Figure 8 Global Cell Viability Assays Market Share, by Region, 2017


Figure 9 North America: Cell Viability Assays Market Share, by Country, 2017


Figure 10 Europe: Cell Viability Assays Market Share, by Country, 2017


Figure 11 Asia-Pacific: Cell Viability Assays Market Share, by Country, 2017


Figure 12 Middle East & Africa: Cell Viability Assays Market Share, by Country, 2017


Figure 13 Global Cell Viability Assays Market: Company Share Analysis, 2017 (%)


Figure 14 Thermo Fisher Scientific: Key Financials


Figure 15 Thermo Fisher Scientific: Segmental Revenue


Figure 16 Thermo Fisher Scientific: Geographical Revenue


Figure 17 Merck KGaA: Key Financials


Figure 18 Merck KGaA: Segmental Revenue


Figure 19 Merck KGaA: Geographical Revenue


Figure 20 Bio-Rad Laboratories: Key Financials


Figure 21 Bio-Rad Laboratories: Segmental Revenue


Figure 22 Bio-Rad Laboratories: Geographical Revenue


Figure 23 G E Healthcare: Key Financials


Figure 24 G E Healthcare: Segmental Revenue


Figure 25 G E Healthcare: Geographical Revenue


Figure 26 Danaher Corporation: Key Financials


Figure 27 Danaher Corporation: Segmental Revenue


Figure 28 Danaher Corporation: Geographical Revenue


Figure 29 Becton, Dickinson and Company: Key Financials


Figure 30 Becton, Dickinson and Company: Segmental Revenue


Figure 31 Becton, Dickinson and Company: Geographical Revenue


Figure 32 Promega Corporation: Key Financials


Figure 33 Promega Corporation: Segmental Revenue


Figure 34 Promega Corporation: Geographical Revenue


Figure 35 Biotium: Key Financials


Figure 36 Biotium: Segmental Revenue


Figure 37 Biotium: Geographical Revenue


Figure 38 Abcam plc: Key Financials


Figure 39 Abcam plc: Segmental Revenue


Figure 40 Abcam plc: Geographical Revenue


Figure 41 Creative Bioarray: Key Financials


Figure 42 Creative Bioarray: Segmental Revenue


Figure 43 Creative Bioarray: Geographical Revenue


Figure 44 Biotek Instruments: Key Financials


Figure 45 Biotek Instruments: Segmental Revenue


Figure 46 Biotek Instruments: Geographical Revenue


Figure 47 PerkinElmer: Key Financials


Figure 48 PerkinElmer: Segmental Revenue


Figure 49 PerkinElmer: Geographical Revenue